Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Augmentin patent ruling

Executive Summary

Four generic versions of Augmentin will remain on the market following a Federal Circuit decision that affirmed a ruling invalidating GlaxoSmithKline's patents for nonstatutory double patenting. Novartis' Geneva division launched the first generic version of the antibiotic in June 2002. Ranbaxy, Teva and Novartis' Lek division also market generic amoxicillin/clavulanate. Novartis has been placing Geneva's earnings from the generic in reserve in case the company lost the appeal (1"The Pink Sheet" Aug. 5, 2002, p. 35)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS042903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel